WO2022078403A1 - Composé de pyridone substitué et application - Google Patents

Composé de pyridone substitué et application Download PDF

Info

Publication number
WO2022078403A1
WO2022078403A1 PCT/CN2021/123577 CN2021123577W WO2022078403A1 WO 2022078403 A1 WO2022078403 A1 WO 2022078403A1 CN 2021123577 W CN2021123577 W CN 2021123577W WO 2022078403 A1 WO2022078403 A1 WO 2022078403A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
phenyl
Prior art date
Application number
PCT/CN2021/123577
Other languages
English (en)
Chinese (zh)
Inventor
李桢
唐锋
刘乐
赵春艳
陈平
唐任宏
任晋生
Original Assignee
江苏先声药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏先声药业有限公司 filed Critical 江苏先声药业有限公司
Priority to CN202180070837.1A priority Critical patent/CN116782903A/zh
Publication of WO2022078403A1 publication Critical patent/WO2022078403A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La présente invention concerne un composé représenté dans la formule générale (A) ou un sel pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique, un procédé de préparation du composé, ainsi qu'une utilisation du composé en tant qu'inhibiteur de MAT2A.
PCT/CN2021/123577 2020-10-15 2021-10-13 Composé de pyridone substitué et application WO2022078403A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180070837.1A CN116782903A (zh) 2020-10-15 2021-10-13 取代的吡啶酮化合物及应用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202011105645 2020-10-15
CN202011105645.3 2020-10-15
CN202110182410.2 2021-02-10
CN202110182410 2021-02-10
CN202110361446.7 2021-04-02
CN202110361446 2021-04-02

Publications (1)

Publication Number Publication Date
WO2022078403A1 true WO2022078403A1 (fr) 2022-04-21

Family

ID=81207733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/123577 WO2022078403A1 (fr) 2020-10-15 2021-10-13 Composé de pyridone substitué et application

Country Status (2)

Country Link
CN (1) CN116782903A (fr)
WO (1) WO2022078403A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012507A1 (fr) * 2022-07-13 2024-01-18 上海海和药物研究开发股份有限公司 Inhibiteur de mat2a de type bicyclique et son utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051212A1 (fr) * 2009-10-28 2011-05-05 Basf Se Utilisation de composés hétéroaromatiques en tant qu'herbicides
CN104350059A (zh) * 2012-03-27 2015-02-11 拜耳知识产权有限责任公司 具有除草和杀虫活性的噻唑并吡啶酮
CN107108654A (zh) * 2014-12-22 2017-08-29 先正达参股股份有限公司 作为除草剂的噻唑并吡啶酮
WO2018045071A1 (fr) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires
WO2018039972A1 (fr) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011051212A1 (fr) * 2009-10-28 2011-05-05 Basf Se Utilisation de composés hétéroaromatiques en tant qu'herbicides
CN104350059A (zh) * 2012-03-27 2015-02-11 拜耳知识产权有限责任公司 具有除草和杀虫活性的噻唑并吡啶酮
CN107108654A (zh) * 2014-12-22 2017-08-29 先正达参股股份有限公司 作为除草剂的噻唑并吡啶酮
WO2018045071A1 (fr) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires
WO2018039972A1 (fr) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibiteurs de processus métaboliques cellulaires

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024012507A1 (fr) * 2022-07-13 2024-01-18 上海海和药物研究开发股份有限公司 Inhibiteur de mat2a de type bicyclique et son utilisation

Also Published As

Publication number Publication date
CN116782903A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
TWI694078B (zh) 吡咯並三嗪類衍生物、其製備方法及其用途
CN106928219B (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
WO2018113584A1 (fr) Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
CN110506043A (zh) 适用作ret抑制剂的化合物
KR20090071612A (ko) 단백질 키나제 조정제로서의 바이시클릭 트리아졸
CN110461841B (zh) 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
WO2022214053A1 (fr) Inhibiteur de la protéase spécifique de l'ubiquitine 1 (usp1)
US9156853B2 (en) AKT inhibitor compounds for treatment of cancer
WO2021254529A1 (fr) Composé bicyclique
CN113166156A (zh) 酪氨酸激酶抑制剂、组成及其方法
TW202204351A (zh) 具有大環結構的化合物及其用途
WO2021032004A9 (fr) Composé d'azahétéroaryle et son utilisation
WO2018121766A1 (fr) Composé hétérocyclique fusionné contenant de l'azote, procédé de préparation, intermédiaire, composition et utilisation associés
CN114874207A (zh) 作为mat2a抑制剂的双环类化合物
WO2022078403A1 (fr) Composé de pyridone substitué et application
WO2020221209A1 (fr) Inhibiteur de cd73, son procédé de préparation et son utilisation
WO2023036252A1 (fr) Dérivé de pyrrolopyrimidine ou de pyrrolopyridine et son utilisation médicale
WO2020057669A1 (fr) Composé hétérocyclique aromatique ayant une activité inhibitrice de kinase
CN114195771A (zh) 多激酶抑制剂及其用途
WO2022052924A1 (fr) Procédé de préparation de composés cycliques fusionnés contenant de l'azote et leur utilisation
WO2021129561A1 (fr) Composé de pyridine à substitution cyano et composé de pyrimidine à substitution cyano, et leur procédé de préparation et leur utilisation
CN113072551A (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
WO2020233645A1 (fr) Dérivés de macrolides, leur procédé de préparation et leur application
TW202024092A (zh) 氨基嘧啶并五元雜環化合物、其中間體、製備方法、藥物組合物及應用
TWI707853B (zh) 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21879446

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202180070837.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21879446

Country of ref document: EP

Kind code of ref document: A1